Core Insights - Proactive is a financial news and online broadcast organization that provides fast, accessible, and actionable business and finance news to a global investment audience [2][3] - The company specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's editorial and broadcast operations are managed by a seasoned team, ensuring quality control and content production across multiple global locations [1][2] Company Operations - Proactive operates with a team of experienced news journalists across key finance and investing hubs, including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - The organization produces approximately 50,000 pieces of real-time news, feature articles, and filmed interviews annually [1] - Proactive employs both human content creators and technology, including automation and generative AI, to enhance workflows while ensuring all content is edited and authored by humans [4][5] Market Focus - The company delivers news and insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3]

Core Viewpoint - Tiziana Life Sciences is presenting a scientific poster on its Phase 2a clinical trial of intranasal foralumab for treating non-active secondary progressive multiple sclerosis at the ECTRIMS Congress, highlighting its innovative approach in immunomodulation therapies [1][2][4]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using novel drug delivery technologies, particularly intranasal delivery for immunotherapy [6][8]. - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, showing a favorable safety profile and clinical response in preliminary studies [5][8]. Clinical Trial Details - The poster presentation titled "Study Design of a Phase 2a Double-Blind Placebo-Controlled Trial of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis" outlines the trial's design and objectives [2][7]. - The Phase 2a trial aims to evaluate the efficacy and safety of nasal foralumab in patients with non-active secondary progressive multiple sclerosis, a group with limited treatment options [4][5]. Event Information - The ECTRIMS Congress, where the poster will be presented, is the largest annual international conference dedicated to multiple sclerosis research, taking place from September 24-26, 2025, in Barcelona, Spain [1][4][7].

Core Insights - Tiziana Life Sciences Ltd is highlighted as one of the best biotech penny stocks to invest in currently [1] Company Overview - Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a clinical-stage biotech company focused on next-generation immunomodulation therapies for neuroinflammatory and neurodegenerative diseases, including multiple sclerosis, Alzheimer's, and multiple system atrophy [2] Management Activity - In September 2025, significant insider activity was noted, with CEO Ivor Elrifi purchasing 193,848 shares at $1.65 each, and Executive Chairman Gabriele Cerrone acquiring 25,000 shares, increasing his stake to 36.28%, indicating strong management confidence in the company's pipeline and long-term prospects [3] Recent Developments - Tiziana Life Sciences Ltd secured a U.S. Department of Defense grant on September 15, 2025, to advance the development of intranasal foralumab for spinal cord injury, expanding its focus beyond central nervous system disorders [4] - The company achieved a milestone by dosing the first patient in a Phase 2a trial for multiple system atrophy, following FDA approval of a Phase 2 IND application in August 2025 [4]

Group 1 - Berkshire Hathaway has completely divested its shares in BYD, marking the end of a 14-year investment period [10] - The investment was valued at zero as of March 31, 2023, according to Berkshire's financial documents [10] - Over the investment period, Berkshire Hathaway has reduced its holdings in BYD at least 16 times, realizing a profit of at least 8.071 billion HKD [10] Group 2 - The Chinese government is actively working on establishing national standards for pre-prepared dishes to enhance consumer rights [4][6] - The initiative involves multiple departments, including the Ministry of Industry and Information Technology and the National Health Commission [4] Group 3 - A blue alert for Typhoon "Haikui" has been issued, with expectations of severe weather impacting the South China Sea and parts of Guangdong [5] - The typhoon is predicted to approach the northeastern coast of Hainan Island, with maximum wind speeds exceeding 62 m/s [5] Group 4 - A suspected food poisoning incident in Guizhou has led to 136 individuals being hospitalized, with symptoms linked to salmonella contamination [5] - The local authorities are investigating the incident and have taken measures to seal off the affected food products [5] Group 5 - Huawei has launched the "Tian Gong Plan," committing 1 billion RMB to support the development of the HarmonyOS AI ecosystem [8] - The number of devices running HarmonyOS 5 has surpassed 17 million, indicating significant growth in the ecosystem [8]

Core Insights - Proactive provides fast, accessible, and informative business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, mining, oil and gas, and emerging technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - Tiziana Life Sciences has received a research grant from the U.S. Department of Defense to study intranasal anti-CD3 therapy for traumatic spinal cord injury, expanding its therapeutic potential into significant neurological conditions [1][2][3]. Group 1: Research and Development - The DoD grant will fund a three-year study focusing on the acute phase of spinal cord injury, targeting patients who arrive at the hospital immediately after injury [2]. - A complementary two-year Stepping Strong Breakthrough Award will investigate the chronic phase of spinal cord injury, concentrating on patients with ongoing neurological deficits [2]. - Tiziana's lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody that has shown promise in stimulating T regulatory cells and improving disease stability in patients with non-active secondary progressive multiple sclerosis [6][7]. Group 2: Market Opportunity - Traumatic spinal cord injury affects nearly 300,000 Americans with permanent disabilities and sees over 17,000 new injuries each year, representing a significant unmet medical need [3]. - Current treatments are primarily supportive, with no approved therapies that enhance neurological recovery or prevent chronic complications from spinal cord inflammation, indicating a substantial commercial opportunity for Tiziana [3]. Group 3: Mechanism and Benefits - Intranasal anti-CD3 therapy aims to rebalance the immune system, reduce inflammation in the injured spinal cord, and support functional recovery, potentially benefiting other acute central nervous system injuries [4][5]. - Preclinical results have indicated that this non-invasive therapy could improve motor outcomes, enhancing independence and quality of life for patients [4].

BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 193,848 shares of Tiziana common stock at a price of $1.65 per share in the open market. About Foralumab Foralumab, a fully human anti-CD3 m ...

Core Insights - Tiziana Life Sciences has initiated a Phase 2a clinical trial for intranasal foralumab in patients with Multiple System Atrophy (MSA), marking a significant step in developing therapies for this rare neurodegenerative disorder [1][3]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies, particularly through nasal administration [9]. - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, demonstrating a favorable safety profile and clinical response in prior studies [9][7]. Clinical Trial Details - The Phase 2a trial will evaluate the efficacy of foralumab in reducing neuroinflammation and aims to determine its potential to slow disease progression and improve quality of life for MSA patients [3][4]. - The trial involves a six-month open-label study with participants receiving treatment over eight dosing cycles [3]. Disease Context - Multiple System Atrophy is a rare and rapidly progressive neurodegenerative disorder affecting an estimated 15,000–50,000 individuals in the U.S., with no FDA-approved treatments available to alter its course [2][5]. - The disease leads to severe movement, balance, and autonomic function issues, with most patients surviving only 6–9 years post-diagnosis [5]. Mechanism of Action - Foralumab works by stimulating T regulatory cells through a novel, non-systemic delivery approach, targeting the immune processes that may drive neurodegeneration [4][6]. - Early studies have indicated potential benefits of foralumab in stabilizing or improving function in other neuroinflammatory conditions, such as multiple sclerosis [4][6].

Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world's key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. About this content About Emily Jarvie Emily began her career as a political journalis ...

Core Viewpoint - Tiziana Life Sciences has received FDA approval for the IND of its Phase 2a clinical trial of intranasal foralumab for treating Multiple System Atrophy (MSA), addressing an unmet medical need in this orphan disease [1][4]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies, particularly intranasal administration [6][7]. - The company's lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, showing a favorable safety profile and clinical response in previous studies [6][7]. Clinical Trial Details - The Phase 2a study is a six-month, open-label trial aimed at evaluating the effects of intranasal foralumab on microglial activation, clinical outcomes, and safety in MSA patients [2]. - Foralumab is administered via nasal spray in eight 3-week dosing cycles, targeting T-cell mediated neuroinflammation [2]. Disease Context - Multiple System Atrophy is a rapidly progressive neurodegenerative disorder with a mean incidence of 0.6 per 100,000 person-years in the US, increasing to 3 per 100,000 for individuals aged 50 and older [3]. - The disease leads to severe disability and has a poor prognosis, with a median survival of 6-9 years [3]. Mechanism of Action - Foralumab induces regulatory T cells and modulates T-cell-driven inflammation, potentially slowing neuronal damage in neuroinflammatory and degenerative diseases [4]. - The therapy aims to impact microglial activity and clinical outcomes significantly over the trial period [4].